⚠️ Compounded Tirzepatide Recall: What to Know About the Apothecary Pharma Lots

A compounding pharmacy has voluntarily recalled 22 lots of its compounded tirzepatide, a copycat version of the active ingredient in Eli Lilly’s Zepbound. 🧪 Here are the facts from the FDA’s recall record, plus the bigger picture on compounded GLP-1s.

📰 What Happened

According to the FDA’s enforcement report, Apothecary Pharma LLC of Cary, North Carolina, recalled its Tirzepatide Injection, 18 mg/mL, sold in 4 mL sterile multi-dose vials (NDC 85091-001-18). The reason listed is “lack of assurance of sterility,” which means the company couldn’t confirm the product was free of contamination. BioPharma Dive, which reported the recall on Oct. 22, says the company’s notice stated it couldn’t definitively guarantee the medication’s safety.

Here are the key details from the FDA record:

Lots: AP-202622 through AP-202625 and AP-202627 through AP-202644, for 22 lots in total.

Beyond-use dates: Oct. 7 through Nov. 26, 2026.

Distribution: Nationwide in the U.S.

Timeline: The company started the recall by letter on Sept. 24. The FDA classified it on Oct. 8 and listed it in its Oct. 14 enforcement report, where its status was “ongoing.”

The FDA rated it a Class II recall. Under FDA definitions, that means the product could cause temporary or medically reversible health problems, or the chance of serious harm is remote.

🔙 The Backstory

Compounding pharmacies make customized versions of medicines. Compounded drugs aren’t FDA-approved, and the FDA says it doesn’t review them for safety, effectiveness or quality before they’re sold.

When tirzepatide and semaglutide were in shortage, compounders were allowed to make copies, and those copies took off. That window has closed. The FDA declared the tirzepatide shortage resolved in December 2024 and the semaglutide shortage resolved in February 2025, and its grace periods for compounders ended in 2025. In an April 2026 update, the FDA said neither drug was on its shortage list.

BioPharma Dive reports that many companies kept selling compounded versions by personalizing treatment, which federal law allows. It cites a Gallup survey finding that about 20% of Americans on these medicines use compounded forms. Lilly and Novo Nordisk, the only makers of FDA-licensed GLP-1 obesity medicines, have sued to shut down the copycat market.

The FDA has also flagged its own concerns. As of May 31, 2026, it had received more than 730 adverse event reports tied to compounded tirzepatide. The agency notes it can’t always tell whether the drug caused a reported problem, and it says these reports are probably undercounted.

🔮 What’s Next

The recall was still listed as ongoing in the FDA’s latest report. BioPharma Dive suggests recalls like this one could strengthen Lilly’s and Novo’s argument that compounded versions don’t match the quality, safety or effectiveness of the approved drugs. Meanwhile, the FDA continues to warn telehealth companies and ingredient suppliers about unapproved GLP-1 products.

🩺 Questions About Your Medication?

If you have any questions about your medication, including whether a vial might be part of this recall, contact your pharmacist or doctor. They can check the details with you and talk through your options.

💬 Come Chat With the Flock

How do you keep track of the lot numbers and dates on your medication? Share your system in the Tideflock community forum. 🐦

📚 Sources

FDA Enforcement Report: Apothecary Pharma LLC recall D-0036-2027

BioPharma Dive: GLP-1 compounder issues recall for copycat Zepbound (Oct. 22, 2026)

FDA: FDA’s concerns with unapproved GLP-1 drugs used for weight loss

FDA: FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize